# US 2024/0254659 A1 · Systems and methods for regulating target genes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254659 A1
- Document ID: US20240254659A1
- Status: Published application
- Kind: A1
- Application number: 18/417,827
- Filed: 2024-01-19
- Published: 2024-08-01
- Earliest claimed: 2021-07-20
- Assignees: Epicrispr Biotechnologies, Inc.
- Applicants: Epicrispr Biotechnologies, Inc.
- Inventors: Daniel O. Hart; Lei S. Qi; Timothy Daley; Thomas Blair Gainous; Giovanni Carosso; Tengyu Ko; Robin W. Yeo; Christopher Darryl Still, II
- Web page: https://patentgrep.com/patent/US20240254659A1

## CPC

- C40B 30/06: by measuring effects on living organisms, tissues or cells
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/12: in functional genomics, i.e. for the determination of gene function
- C12N 2330/31: Libraries, arrays
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The disclosure provides compositions, methods, and systems for modulating expression of target genes (e.g., target endogenous genes). Complexes of the disclosure can be useful for bringing one or more heterologous gene effectors into close proximity with a target gene or target gene regulatory sequence, thereby facilitating modulation of an expression or activity level of the target gene. The disclosure provides, for example, compositions, systems, and methods for high throughput screens to identify heterologous gene effector domains and complexes of the effector domains with guide moieties to modulate expression of particular target gene(s). The disclosure also provides complexes identified by systems disclosed herein that can be employed for other purposes, such as research or as therapeutics.

## Claims

### Claim 1

(canceled)

### Claim 2

A method, comprising:
(a) contacting a population of cells with a library of complexes, wherein an individual complex of the library comprises:
(i) a heterologous gene effector that is different from heterologous gene effectors in other complexes of the library; and
(ii) a guide nucleic acid sequence that exhibits 100% sequence identity to guide nucleic acid sequences in the other complexes of the library,
wherein the heterologous gene effector and the guide nucleic acid sequence form the individual complex that exhibits specific binding to a target endogenous gene in the population of cells, and
wherein the heterologous gene effector comprises a viral gene effector;
(b) upon the contacting, sorting the population of cells based on a change in expression or activity level of the target endogenous gene in the population of cells; and
(c) identifying one or more lead heterologous gene effectors of the library that effect the change.

### Claim at position 3

3-51. (canceled)

### Claim 52

A complex comprising a guide moiety and a heterologous gene effector, wherein the heterologous gene effector comprises an amino acid sequence with at least about 70% sequence identity to any one of SEQ ID NOs: 23631, 1102, 2057, 5543, 9066, 11948, 15646, 17629, 19860, 21015, 21166, 22149, 22707, 23639, 25430, 25555, 32678, 33890, 34047, 35737, 38138, 38780, 40913, 40985, 40986, or 42623.

### Claim 53

(canceled)

### Claim 54 (depends on 52)

The complex of claim 52, wherein the heterologous gene effector comprises the amino acid sequence of any one of SEQ ID NOs: 23631, 1102, 2057, 5543, 9066, 11948, 15646, 17629, 19860, 21015, 21166, 22149, 22707, 23639, 25430, 25555, 32678, 33890, 34047, 35737, 38138, 38780, 40913, 40985, 40986, or 42623.

### Claim 55 (depends on 52)

The complex of claim 52, wherein the amino acid sequence has at least 90% sequence identity to SEQ ID NO: 23631.

### Claim 56

(canceled)

### Claim 57 (depends on 52)

The complex of claim 52, wherein the amino acid sequence has at least 90% sequence identity to SEQ ID NO: 33890.

### Claim 58

(canceled)

### Claim 59 (depends on 52)

The complex of claim 52, wherein the amino acid sequence has at least 90% sequence identity to SEQ ID NO: 40985.

### Claim 60

(canceled)

### Claim 61 (depends on 52)

The complex of claim 52, wherein the heterologous gene effector contains less than 500 amino acids.

### Claim 62

(canceled)

### Claim 63

(canceled)

### Claim 64 (depends on 52)

The complex of claim 52, wherein the guide moiety comprises a guide nucleic acid sequence.

### Claim 65 (depends on 64)

The complex of claim 64, wherein the guide nucleic acid sequence comprises between about 10 and about 30 nucleotides.

### Claim 66 (depends on 64)

The complex of claim 64, wherein the guide nucleic acid sequence is a guide RNA.

### Claim 67

(canceled)

### Claim 68 (depends on 52)

The complex of claim 52, wherein the guide moiety comprises a nuclease or a part thereof.

### Claim at position 21

69-71. (canceled)

### Claim 72 (depends on 68)

The complex of claim 68, wherein the nuclease or part thereof is a nuclease deactivated Cas (dCas) protein or part thereof.

### Claim 73 (depends on 52)

The complex of claim 52, the guide moiety and the heterologous gene effector are fused to each other.

### Claim 74 (depends on 52)

The complex of claim 52, wherein the guide moiety and the heterologous gene effector are non-covalently coupled to each other.

### Claim 75

(canceled)

### Claim 76

(canceled)

### Claim 77 (depends on 52)

A vector comprising the complex of claim 52.

### Claim 78 (depends on 52)

A vector comprising a nucleic acid that encodes the heterologous gene effector of claim 52.

### Claim 79 (depends on 78)

The vector of claim 78, wherein the vector further comprises a nucleic acid that encodes the guide moiety or a component thereof.

### Claim 80

(canceled)

### Claim 81

(canceled)

### Claim 82 (depends on 52)

A population of cells comprising the complex of claim 52.

### Claim 83 (depends on 52)

A method of modulating expression or activity of a target gene, the method comprising contacting a population of cells that comprise the target gene with the complex of claim 52.

### Claim at position 34

84-89. (canceled)

### Claim 90 (depends on 52)

A method of treating a subject in need thereof, the method comprising administering to the subject the complex of claim 52, thereby modulating expression or activity of a target gene in a population of cells in the subject.

### Claim at position 36

91-103. (canceled)

### Claim 104

An expression vector comprising: a plurality of heterologous polynucleotide sequences, wherein each heterologous polynucleotide sequence of said plurality of heterologous polynucleotide sequences exhibits at least about 80% sequence identity to the polynucleotide sequence of any one of SEQ ID NOs: 49334-49338.

### Claim 105

A nucleic acid molecule comprising:
a heterologous polynucleotide sequence is a chimeric sequence comprising (i) a CRISPR target sequence and (ii) a CRISPR protospacer adjacent motif (PAM) sequence and an additional CRISPR PAM sequence that are different,
wherein said CRISPR target sequence is flanked by said CRISPR PAM sequence and said additional CRISPR PAM sequence.

### Claim 106

A nucleic acid molecule comprising:
a plurality of heterologous polynucleotide sequences, wherein:
(i) each heterologous polynucleotide sequence of said plurality of heterologous polynucleotide sequences comprises a polynucleotide sequence and an additional polynucleotide sequence that are derived from different human chromosomes; and
(ii) a size of said each heterologous polynucleotide sequence is at most about 50 nucleobases.
